The National Pharmaceutical Pricing Authority (NPPA) has sharply cut prices of various formulations and bulk drugs. While the price cuts in the bulk drugs category go up to 47 per cent, formulation prices have been reduced by up to 60 per cent.
Nicholas Pirama, Cadila and Ranbaxy are among the companies whose products have been affected by the price fixations and ceilings.
The prices have been fixed for the first time in the case of 25 formulation packs, mainly insulin based formulations, while in case of 23 packs, the prices have been revised downward, ranging from 0.73 per cent to 60 per cent.
Out of these 23 packs, the prices of 16 packs were revised on suo-motu basis as per the provisions of the DPCO, 1995 as the manufacturers, though required to apply for price revision, did not do so.
Among the suo-moto cases is a 12.42 per cent cut in prices of ranitidine 150 mg tablets to Rs 5.64 per 10
